Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

This is a long-term safety follow-up study for patients who previously received a special type of immune cell therapy — called lentiviral-based gene-edited immune cell therapy — in a clinical trial. The goal is to monitor participants for up to 15 years to make sure the treatment remains safe over time. **You may be eligible if...** - You previously received lentiviral-based gene-edited immune cell therapy (from Pell's) as part of a clinical trial - Your last infusion of that therapy was within the past 15 years - You (or your legal guardian) are able to provide informed consent **You may NOT be eligible if...** - You have never received this specific type of gene-edited immune cell therapy - There are no other specific exclusion criteria for this study Talk to your doctor to see if this trial is right for you.